The completion of the human genome project in 2003 represented a major scientifi c landmark, ushering in a new era with hopes and expectations of fresh insights into disease mechanisms and treatments. In infl ammatory bowel disease (IBD), many important discoveries soon followed, notably the identifi cation of >200 genetic susceptibility loci and characterization of the gut microbiome. As "big data", driven by advances in technology, becomes increasingly available and affordable, individuals with IBD and clinicians alike yearn for tangible outcomes from the promise of "precision medicine"-precise diagnosis, monitoring, and treatment. Here, we provide a commentary on the prospects and challenges of precision medicine and biomarkers in IBD. We focus on the three key areas where precision IBD will have the most impact: (1) disease susceptibility, activity, and behavior; (2) prediction of drug response and adverse effects; and (3) identifi cation of subphenotypic mechanisms to facilitate drug discovery and selection of new treatments in IBD. innovation is emerging with synergy arising from novel ideas within established and fresh data sets.
PRECISION MEDICINE IN IBD
Precision medicine is a major priority in health care, now recognized by all major stakeholders including governments, the pharmaceutical industry, clinicians and patients. In January 2015, United States President Barack Obama announced the Precision Medicine Initiative (PMI): a concerted eff ort by multiple government agencies and backed by $215 million in federal funds to help facilitate a greater understanding of individual disease variability and its clinical translation ( 1 ) . A major component is the PMI Cohort Program, an ambitious plan to build a national research cohort of more than one million participants in a participantcentered, data-driven framework with integrated multi-omic profi ling. Th e PMI working group's report ( 2 ) identifi ed key scientifi c opportunities including a number relating to the importance of biomarkers ( Box 1 ). Similarly, the Chinese government has plans to invest 20 billion yuan (around US $3 billion) to support precision medicine research by 2030. Here in the UK, the 100,000 genomes project was launched in 2012 with the goal of large-scale integration of genetic information and health records from the National Health Service ( http://www.genomicsengland.co.uk ).
In the same year, the National Phenome Centre was launched in the UK, off ering broad access to exploratory and targeted highthroughput metabolic phenotyping and computational biology facilities. Th ese massive undertakings are game changers in the fi eld of biomarker discovery and validation.
In IBD, successful international partnerships in genetics and microbiome research already provide grounds for realistic optimism. A major concern remains the wide-ranging nature of the stochastic elements of IBD, which represent formidable hurdles with respect to study design and measurable outcomes. A recent study published in Cell ( 3 ) provides a concrete conceptual framework on how unbiased, data-driven development of personalized medicine approaches may be applicable to IBD. In this proof-of-concept study, post-prandial glucose responses to 46,898 meals were measured in 800 patients using continuous blood glucose monitoring. Combining patient-entered data with clinical and microbiota profi les, a computational algorithm was developed that accurately predicted personalized glycaemic response in a separate cohort. Notably, this algorithm was used in a follow-up dietary intervention study which yielded signifi cantly lower post-prandial glucose levels ( 3 ). In our fi eld, current creative research approaches (discussed in detail later) are now beginning to integrate across molecular data sets (e.g., genetic+microbiome), override traditional boundaries of disease classifi cations (UC vs. CD), target previously underexplored biological systems (e.g., virome and endogenous DAMPs), and most notably, increasingly rely on patient input using new technological applications to characterize the "exposome" in IBD (4) (5) (6) . Th e "exposome" will be an important factor in analytical approaches involving multi-omic panels, including novel and established environmental factors. Of the these, smoking will be the most infl uential ( 7 ) given its recognized roles in predicting disease behavior in IBD; and therapeutic response for anti-TNF treatment in CD ( 8 ) . Hence, a new theme of recombinant
IBD BIOMARKERS IN CLINICAL PRACTICE-THE STORY SO FAR
Numerous potential genetic, blood-based, fecal, microbial, and immunological biomarkers have been proposed in IBD ( 9 ) ( Table 1 ) . Th is has recently been extensively reviewed (10) (11) (12) (13) . However, apart from a few notable exceptions, biomarkers have not yet found widespread clinical application in IBD practice for a variety reasons ( Box 2 ). We highlight three examples of "biomarkers" that have roles in clinical practice, namely fecal calprotectin (FC), anti-TNF antibodies, and thiopurine methyltransferase activity measurements. FC is a screening tool for gut infl ammation ( 15 ) and to measure disease activity in IBD ( 16 ) . More recently, the potential to use FC in innovative ways has been explored including as a predictive tool (e.g., to identify disease recurrence in post-operative CD ( 17 ) ) and as a secondary end point in IBD clinical trials. Detection of anti-TNF antibodies allows for expedient switching to an alternative drug ( 18 ) and avoids conventional dose escalation which is oft en futile, expensive, and potentially hazardous ( 19 ) . Th erapeutic drug monitoring and antibody testing are important recent developments that are used to inform dosing or the decision to switch biological. A recent randomized-controlled trial in the setting of secondary loss of response to infl iximab compared conventional dose intensifi cation with an algorithm-based approach based on serum infl iximab levels and antibodies ( 20 ) . Here, management dictated by drug levels and antibodies was found to be cost eff ective with no reduction in clinical effi cacy. Th erapeutic drug monitoring of anti-TNF is emerging as a logical step in the clinical management algorithm. However, early data from a randomized-controlled trial comparing symptom-based dosing with symptom-/biomarker-/drug level-based dosing in CD (TAILORIX study) casts some uncertainties ( 21 ) . Specifi cally, initial results published in abstract form suggest that proactive trough level-based dose intensifi cation was not superior compared with dosing based on symptoms alone-fi nal results are eagerly awaited. Furthermore, satisfactory serum anti-TNF levels do not necessarily correlate to tissue concentrations and clinical response ( 22 ) . Th iopurine methyltransferase measurement can screen for those who are likely to experience life-threatening leukopenia from thiopurines ( 23 ) and those who would benefi t from a reduced initial dose. Th iopurine metabolite levels are now used to identify underdosing, poor compliance, and thiopurine hypermethylation, allowing for dose optimization ( 24 ) . Although of some clinical benefi t, these currently available examples provide some perspective to the enthusiasm toward Precision Medicine, highlighting the wide gulf between what clinicians currently have at their disposal and the ambitious aspirations for the near future. • Biomarker discovery for identifi cation of individuals with higher risks of developing disease to help more rational prevention eff orts. • Interrogation of the wide variation in therapeutic response and adverse reactions.
• Novel classifi cation systems which transcend existing grouping based on symptoms, signs, and laboratory results by using molecular characterization. • Using biomarkers to stratify patients into clinical trials to target subsets and help with development of novel therapies.
• Translating pre-existing environmental and genetic risk factors into conclusions on disease causes and population impact with population-based cohort studies as well as identifying new associations.
IBD BIG DATA: SINK OR SWIM?
Th e critical question is: are we on the cusp of a therapeutic revolution underpinned by the inexorable wave of big data, or will we end up drowning in a sea of potential biomarkers that we cannot translate into clinical practice? A number of critical enablers allow for optimism ( Figure 1 ). First, government and industry interest and investment will continue to improve the development of large-scale prospective cohorts. Ambitious biobank projects such as the recently launched UK-wide IBD BioResource ( www. ibdbioresource.nihr.ac.uk ) and the aforementioned PMI Cohort Program will help overcome this fi rst obstacle for novel IBD biomarker discovery and validation. Second, we expect advances in high-throughput technology to allow for quicker, cheaper, and more effi cient testing of large biobanks. Costs for DNA sequencing have shrunk by >10 million fold since 1998-something almost inconceivable at the time. It is similarly diffi cult to comprehend what might be possible in the future. In concert, advances in computational power will continue to facilitate production and analysis of massive amounts of accrued data. Th e computing resources required to deal with data from -Omics work in IBD is substantial. Th ird, we foresee the infl uence of the exposome being clarifi ed from an increasing emphasis on patient inputted data. Technological advances such as personal mobile devices for realtime monitoring and electronic health record integration will provide a platform for prospective and progressive data collection. In IBD, there is increasing use of real-time feedback of clinical information, environmental factors and disease activity (e.g., home FC kits) back to clinicians and researchers ( 25 ) . 
Box 2 . Why have most potential IBD biomarkers not found themselves in widespread clinical use?
• Failures on the classic qualities of an ideal biomarker ( 14 ) (simple, accurate, easy to perform, minimally invasive, cheap, rapid, and reproducible).
• Unclear or uncertain clinical utility: i.e., does not provide clinically useful information upon which to make decisions 1 . low sensitivity/specifi city 2 . low prognostic/predictive values
• Lack of validation in independent cohorts or have had inconsistent results when validation has been attempted.
• Some areas (such as microbiome-based biomarkers) are in their infancy.
Th ese advancements require even closer levels of cooperation and collaboration between researchers. Furthermore, there is a greater need for more creative analytical approaches that will involve a model of continuous learning and analysis. Centers of excellence dedicated to Precision Medicine and Big Data analyses are now currently being set up globally. Some health systems may be better equipped to provide the long-term biological data and clinical follow-up that captures the disease population in its widest sense (e.g., arguably, the UK National Health System).
Notwithstanding all these major interventions, a dose of realism is required. In cancer research, where investment has been far greater, there has been a decrease in the number of FDA-approved protein biomarkers over the last decade ( 26 ) . In IBD, it is notable that existing biomarkers such as FC were found through hypothesis-based investigation ( 27 ) rather than high-throughput methods or in silico database analysis. Presently, there are signifi cant challenges in discovery-based approaches (summarized in Box 3 ). In particular, selection bias from convenience sampling and data overfi tting can result in over-interpretation of "signifi cant" P values, potentially wasting valuable resources on random noise. For example, a host of studies have identifi ed genetic polymorphisms as predictors of therapeutic response in IBD ( 10 ) but these have not been consistently replicated. Th ere remains room for advancements based on discoveries in related infl ammatory conditions, serendipity, and organic scientifi c thinking although big data now forms the ground for the generation of new hypotheses.
PRECISION MEDICINE IN IBD: RECENT PROGRESS
Multiple lines of evidence show progress toward Precision Medicine and we provide a brief overview of several promising studies in three key areas in IBD (disease susceptibility, activity, and behavior; prediction of drug response and adverse eff ects; and identifi cation of subphenotypic mechanisms for drug selection and discovery). Collectively, they highlight a few recurrent themes. First, the enormous potential of how big data can be even more powerful when diff erent data platforms are integrated. Second, the process involved in validating these increasingly complex fi ndings, and the path for biomarkers to reach clinical application, remains diffi cult. In this context, it seems likely that the future maybe based on computational predictive modeling, incorporating many biomarkers as shown by Zeevi et al. ( 3 ) , and evident in artifi cial intelligence systems that permeate current daily living (e.g., weather forecasting and voice recognition search systems). Th is challenges the traditional criteria for a good biomarker being simple, accurate, easy to perform, minimally invasive, cheap, rapid, and reproducible. Hence, some re-orientation of IBD patients' and clinicians' perspectives may be needed.
Disease susceptibility, activity, and behavior
Here, genetic studies lead the way with the latest meta-analysis now involving 50,000 IBD individuals implicating >200 susceptibility loci ( 28, 29 ) . Th is information provided hitherto unknown insights into disease mechanisms and biological pathways such as autophagy and IL23/Th 17. Furthermore, genetic testing is useful in very early onset IBD to identify rare genetic defects, allowing for genetic counseling for family members as well as • Large costs associated with biomarker validation for those biomarkers proposed by unbiased -Omics testing.
• Potential confounders including interaction between the diff erent "omes" (e.g., microbiome studies with eff ect of host genome), disease activity, duration, location and eff ects of drug treatment, study design, and heterogeneous cohorts.
• Selection bias using convenience sampling.
• Increased fl exibility and non-linearity in algorithms leading to overfi tting.
• Lack of support from pharmaceutical companies not wanting to fragment markets.
• Reluctant adoption and acceptance by physicians and patients.
• Mainly cross-sectional studies so far rather than data from prospective studies.
• Electronic medical record integration-diffi culties in standardization, poor quality, and granularity of inputted data. National approach easier in some countries (e.g., UK with NHS) than others, e.g., USA.
• Privacy and data security.
• Standardization of all steps in the process of biomarker discovery is optimal but in practice, diffi cult to achieve.
• Teamwork and collaboration across institutions (particularly critical in relatively low-incidence diseases such as IBD) with use of standard protocols and large cohorts.
Potential Solutions • Data-driven approaches such as network interference.
• Prospective studies with multiple time points.
• Standardized method of sample acquisition.
• Use of homogenous patient subsets and studies of subjects with no prior medical therapy.
have better negative predictive values and are thus more useful in excluding signifi cant infl ammatory signals. Some progress can be expected in modalities to image infl ammation (MRI) with or without the use of specifi c in vivo labeling of infl ammatory cells or targets. A recent study used confocal laser endomicroscopy to detect fl uorescent antibody-labeled membrane-bound TNF (mTNF) in intestinal immune cells of 25 CD patients ( 49 ) . Patients with high numbers of mTNF+ cells were more likely to respond to adalimumab at week 12 than those with low amounts of mTNF+ cells (92 vs. 15%). Furthermore, a re-thinking of ways to measure established biomarkers such as measuring serum (rather than fecal) calprotectin ( 50 ) may improve the performance and applicability of these tests. In search of better disease activity prediction, current approaches as exemplifi ed by the EMBARK study, assess a panel of biomarkers by their correlation with endoscopy and radiological fi ndings as the best reference measure ( 51 ). However, although such reference measures capture disease extent; location and burden well, they are not specifi c enough to evaluate disease behavior, complications, and progression ( 51,52 ). As will be discussed later, better biomarkers of activity may come from a refi ned approach measuring specifi c downstream eff ects of the biological pathway targeted (e.g., Th 17-family of cytokines in IL23/IL17 inhibition).
Prediction of drug response and adverse effects
Exploiting the wealth of genetic data, the combination of phenotypic information with multiple susceptibility loci is shown to be predictive of primary non-response in anti-TNF therapy in pediatric IBD ( 53 ) . Th ere have been some notable successes in transcriptomics (gene expression) in IBD. Lee et al. ( 54 ) showed that CD8+ T-cell immune signatures are better at predicting disease course than traditional clinical or serological markers. Hence, this approach is useful to select individuals that might benefi t from more aggressive medical treatments. At the mucosal level, one study of infl iximab in UC used gene signatures to separate responders from non-responders with 95% sensitivity and 85% specifi city ( 55 ) .
In terms of predicting adverse eff ects, a recent study found that a nonsynonymous single-nucleotide polymorphism in NUDT15 has a greater eff ect than thiopurine methyltransferase variants in patients of Korean ancestry in predicting thiopurine induced leukopenia ( 56 ) . GWAS of azathioprine induced pancreatitis found increased susceptibility for HLA-DQA1-HLA-DRB1 variants with a 2.5-fold increased risk in heterozygotes and a 5-fold increased risk in homozygotes at rs2647087 ( 57 ) . Although an important fi nding, this potential biomarker highlights the diffi culties in translation to the clinic. For example, the low pre-test probability of pancreatitis means that even in the highest risk homozygotes, there is an 83% chance of taking thiopurines without developing pancreatitis. Would this justify the exclusion of thiopurines in these patients? Perhaps not, but in a future of greater therapeutic options, this may be more feasible and in the meantime, will improve risk counseling and awareness. In addition, the number needed to test in this study was 76, making it an expensive option for screening. However, cheaper point of care testing in the future, treatment options such as stem cell transplantation in IL-10R defi ciency ( 30, 31 ) . Apart from this however, the role for genetic data in predicting susceptibility, activity, and disease behavior is less strong. Genetic information allied with other biological data (e.g., pheno-genomic status) or exposome (e.g., smoking) maybe more informative. Th e strongest genetic signal, NOD2 status has been associated with ileal and fi brostenosing disease but carriage of the NOD2 mutant allele is uncommon. A combination of clinical, serological, and genotypic data has been used to help predict the risks of surgery in CD ( 32 ) . Recently, a study of 29,838 IBD patients which tested for genetic-phenotype associations found that predictive models based on generated genetic risk scores strongly distinguished colonic from ileal CD ( 33 ) .
Beyond genetics, epigenetics is emerging as a further tier of information that could complement genome-wide association studies (GWAS) ( 34 ) . Several epigenome wide studies have been published in IBD and other diseases (35) (36) (37) (38) (39) . Th ese studies identify epigenetic mechanisms as a potential interface between genetics and disease. Highly signifi cant enrichment of methylation changes have been shown to occur around GWAS single-nucleotide polymorphisms, in particular the HLA region and MIR21 ( 35 ) . Th e Roadmap Epigenomics Project recently published the most comprehensive epigenomic reference providing information on 111 new reference epigenomes and how these control gene expression in humans ( 40 ) . Equally, other epigenetic mechanisms such as miRNAs are being explored for their roles in IBD pathogenesis ( 41 ) . Th ese short strands of non-coding RNA (~22 nt long) have been shown to regulate key GWAS pathways in IBD including autophagy and epithelial barrier integrity ( 41 ) .
Th e microbiome or "other genome"-the collective genome of the gut microbiota-represents a further giant dimension in big data in IBD and other complex multifactorial conditions such as diabetes and obesity ( 3, 29, 42, 43 ) . Th e NIH-funded Human Microbiome Project Consortium has generated in-depth data on the genomic information and microbial community structure and function in humans ( 44 ) . Some earlier studies show potential for clinical translation toward Precision Medicine. In the largest study of treatment naïve CD patients to date, Gevers et al. ( 45 ) found ileal microbiome signatures were predictive of CD and observed this even in the absence of overt infl ammation. In one recent prospective study of pediatric IBD receiving anti-TNF therapy, fecal microbial diversity resembled controls in patients who responded to anti-TNF therapy vs. non-responders ( 46 ) . Th is shift in microbial diversity in responders was also seen in a pediatric UC study of steroid response ( 47 ) . Furthermore, microbial populations may help predict disease course as illustrated by a study of post-operative recurrence in CD, where a decreased population of Faecalibacterium prausnitzii in the resected ileum correlated with increased risk of recurrence ( 48 ) . We anticipate rapid progress in this area with many opportunities for the public and patients to contribute their fecal samples for analysis (e.g., the American Gut Project).
Away from predicting susceptibility and behavior in IBD, there is an unmet need for sensitive biomarkers to measure gut mucosal infl ammation to provide objective data on disease activity and guide response to treatment. Presently, C-reactive protein and FC and the possible combination with other biomarkers could change the economics of such a test.
Identifi cation of subphenotypic mechanisms to facilitate drug discovery and selection of new treatments
IBD clinicians will have increasing number of drugs available with over 20 currently in the developmental pipeline ( 58, 59 ) . Rather than a sequential approach of trying one drug aft er another, one of the goals for Precision Medicine is to identify individuals or disease phenotypes that are better suited for a particular drug from the outset (e.g., anti-leukocyte migration vs. anti-TNF). Th is direction is appealing and cogent where recent advances in oncology and virology have shown the way. In breast cancer, human epithelial growth factor (HER2) positivity provides prognostic information (more aggressive phenotype with higher recurrence rates) as well as therapeutic choice (response to monoclonal antibodies targeting HER2 such as trastuzumab) ( 60 ) . In metastatic colorectal cancer, KRAS gene mutations predict response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody therapy ( 61 ) . Notably, the early studies were performed based on a hypothesis developed from an understanding of EGFR biology ( 62 ) ; subsequent retrospective subset analysis of randomized-controlled trials provided strong evidence for clinical use. In non-small cell lung cancer, mutations in multiple oncogenes including ALK and EGFR can help direct tyrosine kinase therapy ( 63 ) . In hepatitis C, prior to the direct acting antiviral revolution, IL28B genotype helped predict the likelihood of sustained viral response to interferon and ribavirin therapy.
Th e current case of anti-TNF is instructive and highlights the diffi culties ahead in developing a biomarker-based decision-making model. Th ere is currently no clinically useful predictor of anti-TNF response prior to initiation ( 64 ) . Retrospective studies and post hoc analysis of large clinical trials found a number of phenotypic, demographic and biochemical markers that help predict response but the eff ect size and evidence is not convincing enough to be clinically useful ( 65 ) . At a molecular level, attempts were made to investigate anti-TNF response based on TNF-α gene polymorphisms, but these produced inconsistent results ( 66 ) . Baseline TNF levels were found to be higher in those who did not respond to infl iximab at 10 weeks ( 67 ), but a subsequent larger study did not fi nd any such relationship ( 68 ) . Prediction of anti-TNF response has also been attempted with in vivo imaging ( 69 ) and mucosal gene-expression signatures ( 55, 70 ) . Furthermore, there are ongoing research eff orts to elucidate the factors that determine response to anti-TNF drugs, such as the multi-center UK PANTS study in active luminal Crohn's disease. A more incisive and economical investigative model might be to start from a fresh platform, by building the study of biomarkers into clinical trials in IBD.
INCORPORATING BIOMARKERS IN CLINICAL TRIALS
Th e unexpected failures of secukinumab ( 71 ) and tofacitinib ( 72 ) in CD, anrukinzumab in UC ( 73 ) , and abatacept in CD and UC ( 74 ) have raised the question of whether molecular based stratification with biomarkers based on underlying disease mechanisms could reveal subgroups within the traditional CD and UC groups, who would selectively benefi t from certain therapies ( Figure 2 ) ( 75 ) . A number of large clinical trials are seeking to incorporate biomarkers into trial design ( 76 ) , with notion that biomarker development and clinical trial design should operate hand-inhand. Multiplex IBD biomarker panels are created at diagnosis to obtain a snapshot of a patient's molecular disease profi les. Th ese biomarker profi les can be used in post hoc analyses to investigate their relationship to drug response ( Figure 2 ).
Incorporating new biomarkers in clinical trials however, is challenging and expensive. Th e cost of drug development is inversely related to the size of the target population, which is necessarily smaller in personalized therapy. Furthermore, stratifi cation using 
Study Highlights

WHAT IS CURRENT KNOWLEDGE
✓ Despite recent progress in understanding IBD pathogenesis, there are only a few biomarkers (fecal calprotectin and Creactive protein) that are widely used in clinical practice.
✓ Successful biomarker discovery is hampered by many factors, particularly the wide-ranging nature of the stochastic elements of infl ammatory bowel disease (IBD), which represent formidable barriers to study design and measurable outcomes.
✓ "Big data" in IBD (encompassing host multi-omic profi le, microbiome, and exposome) and increasingly powerful computational approaches are now within reach.
WHAT IS NEW HERE
✓ The Precision Medicine Initiative (PMI) is a major program focused toward achieving a greater understanding of individual disease variability and its clinical translation. Together with many international stakeholders involved in PMI, this impetus represents a game-changer directly relevant to IBD.
✓ We focus on the three key areas where precision IBD will have the most impact: (i) disease susceptibility, activity, and behavior; (ii) prediction of drug response and adverse effects; (iii) identifi cation of subphenotypic mechanisms to facilitate drug discovery and selection of new treatments in IBD.
✓ "Meta-ideas," the pipeline for generating new and innovative ideas to leverage "big data" into tangible clinical translation, now represents the most exciting challenge in biomarker discovery in IBD.
all possible biomarker combinations is impractical given resource and trial participant limitations. At some point, decisions need to be made regarding which biomarkers are incorporated into trials. Another challenge is the standardization of classifi cation/stratifi cation among studies. Although more information, including molecular profi ling, is generally better than less information, distinct and stable classifi cation also has its advantages including comparability between trials, and improved communication between clinicians and researchers. Increasingly targeted therapies will require more defi ned biomarkers to measure their eff ects on the respective biological pathways. Th is sets the scene for stratifi ed clinical trials as seen in oncology for example.
CONCLUSION: META-IDEAS IN IBD
Clinicians long for a future where a newly diagnosed IBD patient can have his/her genetic, microbiome and immune profi le measured at the outset; then matched to the most appropriate biological or immunosuppressive treatment based on likelihood of response/ adverse eff ects. IBD individuals will be given information on what "exposome" to modify and report on their disease activity using the set of optimal biomarkers. At all levels, one can expect a continuous feedback of new data from respective patients, which will further improve the dataset for biomarker discovery. Th is scenario does not detract from or replace the importance of clinician experience and intuition in practically applying this data to the specifi c patient.
For some time, the barrier for real progress has been aff ordable access to big data. Th is is now within reach. Th e digital age now involves patients as active contributors to research data and creates an expansive network of researchers spanning across the traditional disease, biological pathway and systems' boundaries. Th e digitalization of clinical data and penetration of artifi cial intelligence into science are entirely new dimensions in play. Notwithstanding all these factors, we believe that the force that will shape Precision Medicine in IBD will be the focus on meta-ideas-ideas that will further accelerate the production or transmission of new ideas. Established organizations such NASA increasingly rely on "open innovation" or crowdsourcing to fi nd new solutions to their most diffi cult and intractable problems. Th e availability of "big data" is no longer the rate-limiting step to progress; instead, it is the clinician or researcher's ingenuity in leveraging these assets into new knowledge.
